🤯 Have you seen our AI stock pickers’ 2024 results? 84.62%! Grab November’s list now.Pick Stocks with AI

U.S. lawmakers unlikely to get answers from ex-drug executive Shkreli

Published 02/04/2016, 04:41 AM
© Reuters. Former drug executive Shkreli exits the U.S. Federal Courthouse in the Brooklyn borough of New York
WBA
-
BHC
-
HGENQ
-
TVTX
-

By David Ingram and Sarah N. Lynch

NEW YORK/WASHINGTON (Reuters) - Martin Shkreli, the former drug executive who raised the price of a lifesaving medicine by 5,000 percent, is set to appear as a witness at a congressional hearing on Thursday but is unlikely to answer lawmakers' questions about price spikes.

Shkreli, 32, sparked outrage last year among patients, medical societies and Democratic presidential front-runner Hillary Clinton after his company Turing Pharmaceuticals raised the price of 62-year-old Daraprim to $750 a pill from $13.50.

The medicine, used to treat a parasitic infection, once sold for $1 a pill.

The U.S. House Committee on Oversight and Government Reform is scheduled to hold a hearing on drug prices at 9 a.m. EST (1400 GMT), with Shkreli and others from the pharmaceutical industry as witnesses.

For weeks, Shkreli battled with lawmakers. He insisted that if called to appear, he would invoke the Fifth Amendment right against self-incrimination and remain silent. Lawmakers said his testimony was essential to investigating why drug prices had risen and that if he chose not to answer questions, he must do so in person.

Shkreli's lawyer, Benjamin Brafman, repeated on Wednesday that Shkreli would not answer questions. Speaking to reporters after a court hearing, Brafman said the reason was the unrelated criminal charges that Shkreli defrauded investors.

In December, Shkreli was arrested and charged with running his investment funds and companies almost like a Ponzi scheme. He has pleaded not guilty, stepped down from Turing and was fired from KaloBios Pharmaceuticals Inc (PK:KBIOQ). He is also a former head of Retrophin Inc (O:RTRX), which sued him, alleging mismanagement.

The Federal Trade Commission and the New York attorney general are investigating Turing for possible antitrust violations.

Other expected witnesses on Thursday include Turing Chief Commercial Officer Nancy Retzlaff and Valeant Pharmaceuticals (TO:VRX) interim Chief Executive Howard Schiller.

Retzlaff said in written testimony released by the committee that Turing discounted the price of Daraprim to hospitals by 50 percent in November after consulting with patient groups. She added that Turing reinvests much of its income in research and had 13 projects in its pipeline as of December.

Schiller said in written testimony that Valeant has tried to keep drugs affordable through volume-based rebates and a partnership with Walgreens (O:WBA).

He also wrote that patients were best served when prices reflected the market: "When these drugs are priced to reflect more closely their true clinical value, the more accurate price signals incentivize generic competition and innovation."

© Reuters. Former drug executive Shkreli exits the U.S. Federal Courthouse in the Brooklyn borough of New York

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.